Demo
INO Nasdaq· Inovio Pharmaceuticals Inc
FundamentalsNews digest Peer analysis
Login
INO Nasdaq· Inovio Pharmaceuticals Inc
Earnings report Q3 2023

INOVIO Pharmaceuticals Reports Decrease in Revenue for Latest Quarter

Segments of revenue

INOVIO Pharmaceuticals reported revenue of $388.4 million for the three months ended September 30, 2023, compared to $9.2 billion for the same period in 2022. This represents a significant decrease in revenue. For the nine months ended September 30, 2023, the company's revenue was $729.4 million, compared to $10.1 billion for the same period in 2022.

Strengths

Despite the decrease in revenue, INOVIO Pharmaceuticals highlighted several strengths in their financial performance. The company's management attributed the decrease in revenue to various factors, including the settlement of litigation matters and decreases in employee compensation and other outside services related to specific product candidates. These factors were expected and planned for by the company, indicating effective financial management.

Challenges

The decrease in revenue for the latest quarter poses a significant challenge for INOVIO Pharmaceuticals. The company's loss from operations for the quarter was $35.6 million, compared to a loss of $35.8 million for the same period in the previous year. This indicates ongoing financial challenges and the need for the company to address its operating expenses.

Noteworthy

It is noteworthy that INOVIO Pharmaceuticals incurred a net loss attributable to common stockholders of $33.9 million for the three months ended September 30, 2023. The company also reported working capital of $131.1 million and an accumulated deficit of $1.6 billion as of September 30, 2023. These figures highlight the financial difficulties faced by the company and the need for strategic measures to improve its financial position.

Summary

INOVIO Pharmaceuticals experienced a significant decrease in revenue for the latest quarter, which resulted in a loss from operations. However, the company's management addressed the factors contributing to the decrease in revenue, indicating effective financial management. Despite these strengths, INOVIO Pharmaceuticals still faces ongoing financial challenges and needs to address its operating expenses to improve its financial position.

Source documents

Form 10-Q  filed on Nov 09, 2023
78 pages scanned

Reference data

Company financials Q3 revenue 388.4k
Analyst estimates Q3 EPS beat by 4.00%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.